Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;24(6):428–434. doi: 10.1002/clc.4960240603

Clinical benefit of noninvasive viability studies of patients with severe ischemic left ventricular dysfunction

Juan R Soto 1, George A Beller 1,✉
PMCID: PMC6654939  PMID: 11403503

Abstract

The population of patients who have congestive heart failure of ischemic origin is large and growing. It imposes a heavy burden on human suffering and economic costs such as the chronic use of costly medications, recurrent hospital admissions, and, eventually, death or the necessity of heart transplantation. Therefore, the development of methods for detecting viable myocardium may allow the accurate selection of those patients with coronary artery disease with severe left ventricular dysfunction who are most likely to benefit from revascularization, but also excludes patients who are unlikely to obtain any improvement with revascularization techniques. The presence of reversible dysfunctional myocardium that may improve after revascularization implies the concepts of stunned and hibernating myocardium. Recent evidence suggests that hibernation may not be a stable condition since it might evolve toward an irreversible dysfunction if it is not revascularized at the right moment. The techniques available for viability studies are single‐photon emission computed tomography using thallium‐201 or compounds labeled with technetium‐99m, positron emission tomography, and dobutamine stress echocardiography. Newer and promising techniques are magnetic resonance imaging and contrast echocardiography, whose definitive roles are not clear yet. There is abundant evidence from several important studies showing that patients with a significant amount of viable myocardium have a poor outcome if they are treated medically. Conversely, if these patients are revascularized, their outcomes improve and their symptoms significantly decrease, with less necessity of medication, fewer admissions to the hospital, and even in some cases avoiding heart transplantation. On the other hand, patients with poor or no viability who are revascularized do not obtain significant benefit.

Keywords: coronary artery disease; left ventricular dysfunction; myocardial perfusion imaging; myocardial viability; radionuclide imaging; technetium‐99m, thallium‐201

Full Text

The Full Text of this article is available as a PDF (835.6 KB).

References

  • 1. Sharpe N, Doughty R: Epidemiology of heart failure and ventricular dysfunction. Lancet 1998; 352 (suppl I): SI 3–7 [DOI] [PubMed] [Google Scholar]
  • 2. Lahiri A, Senior R: Imaging in ischemic cardiomyopathy: Therapeutic considerations In Nuclear Cardiology: State of the Art and Future Directions. 2nd ed., p. 613 (Eds. Zaret BL, Beller GA.). St. Louis: Mosby, 1999. [Google Scholar]
  • 3. Braunwald E, Rutherford JD: Reversible ischemic left ventricular dysfunction: Evidence for the “hibernating myocardium.” J Am Coll Cardiol 1986; 8: 1467–1470 [DOI] [PubMed] [Google Scholar]
  • 4. Rahimtoola SH: Coronary bypass surgery for chronic angina. A perspective. Circulation 1982; 65: 225–241 [DOI] [PubMed] [Google Scholar]
  • 5. CASS Principal Investigators and Their Associates . Coronary Artery Surgery (CASS): A randomized trial of coronary artery bypass surgery: Survival data. Circulation 1983; 68: 939–950 [DOI] [PubMed] [Google Scholar]
  • 6. Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group : Eleven year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. N Engl J Med 1984; 311: 1333–1339 [DOI] [PubMed] [Google Scholar]
  • 7. Pagley PR, Beller GA, Watson DD, Gimple LW, Ragosta M: Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 1997; 96: 793–800 [DOI] [PubMed] [Google Scholar]
  • 8. Beller GA: Selecting patients with ischemic cardiomyopathy for medical treatment, revascularization, or heart transplantation. J Nucl Cardiol 1997; 4 (2 Pt 2): S152–S157 [DOI] [PubMed] [Google Scholar]
  • 9. Redwood SR, Ferrari R, Marber MS: Myocardial hibernation and stunning: From physiological principles to clinical practice. Heart 1998; 80: 218–222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Vanoverschelde J‐LJ, Wijns W, Depre C, Essamri B, Heyndrickx G, Borgers M, Bol A, Melin JA: Mechanisms of chronic regional postischemic dysfunction in humans: New insights from the study of noninfarcted collateral dependent myocardium. Circulation 1993; 87: 1513–1523 [DOI] [PubMed] [Google Scholar]
  • 11. Gerber BL, Vanoverschelde J‐LJ, Bol A, Michel C, Labar D, Wijns W, Melin JA: Myocardial blood flow, glucose uptake and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction: Implications for the pathophysiology of chronic myocardial hibernation. Circulation 1996; 94: 651–659 [DOI] [PubMed] [Google Scholar]
  • 12. Marinho NVS, Keogh BE, Costa DC, EII PJ, Lammertsma AA, Eli PJ, Camici PG: Pathophysiology of chronic left ventricular dysfunction: New insights from the measurement of absolute myocardial blood flow and glucose utilization. Circulation 1996; 93: 737–744 [DOI] [PubMed] [Google Scholar]
  • 13. Bax JJ, van Eck‐Smit LF, van der Wall EE: Assessment of tissue viability: Clinical demand and problems. Eur Heart J 1998; 19: 847–858 [DOI] [PubMed] [Google Scholar]
  • 14. Vanoverschelde JL, Wijns W, Borgers M, Heyndrickx G, Depre C, Flameng W, Melin J: Chronic myocardial hibernation in humans: From bedside to bench. Circulation 1997; 95: 1961–1971 [DOI] [PubMed] [Google Scholar]
  • 15. Beanlands RS, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD: Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18‐fluorodeoxyglucose positron emission tomography imaging. Circulation 1998; 98 (suppl): II‐51–II‐56 [PubMed] [Google Scholar]
  • 16. Shivalkar B, Maes A, Borgers M, Ausma J, Scheys I, Nuyts J, Mortelmans L, Flameng W: Only hibernating myocardium invariably shows early recovery after coronary revascularization. Circulation 1996; 94: 308–315 [DOI] [PubMed] [Google Scholar]
  • 17. Ramani K, Judd RM, Holly TA, Parrish TB, Rigolin VH, Parker MA, Callahan C, Fitzgerald SW, Bonow RO, Klocke FJ: Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. Circulation 1998; 98: 2687–2694 [DOI] [PubMed] [Google Scholar]
  • 18. Beller GA: Assessment of myocardial perfusion and metabolism for assessment of myocardial viability. Q J Nucl Med 1996; 40: 55–67 [PubMed] [Google Scholar]
  • 19. Mori T, Minamiji K, Kurogane H, Ogawa K, Yoshida Y: Rest‐injected201 thallium imaging for assessing viability of severe asynergic regions. J Nucl Med 1991; 32: 1718–1724 [PubMed] [Google Scholar]
  • 20. Sciagra R, Santoro GM, Bisi G, Pedenovi P, Fazzini PF, Pupi A: Rest‐redistribution thallium‐201 SPET to detect myocardial viability. J Nucl Med 1998; 39: 384–390 [PubMed] [Google Scholar]
  • 21. Udelson JE, Coleman PS, Metherall J, Pandian NG, Gomez AR, Griffith JL, Shea NL, Oates E, Konstam MA: Predicting recovery of severe regional ventricular dysfunction: Comparison of resting scintigraphy with 201TI and 99mTc‐sestamibi. Circulation 1994; 89: 2552–2561 [DOI] [PubMed] [Google Scholar]
  • 22. Sciagra R, Bisi G, Santoro G, Zerauschek F, Sestini S, Pedenovi P, Pappagallo R, Fazzini PF: Comparison of baseline‐nitrate technetium‐99m sestamibi with rest‐redistribution thallium‐201 tomography in detecting viable hibernating myocardium and predicting postrevascularization recovery. J Am Coll Cardiol 1997; 30: 384–391 [DOI] [PubMed] [Google Scholar]
  • 23. Kauffman GJ, Boyne TS, Watson DD, Smith WH, Beller GA: Comparison of rest thallium‐201 imaging and rest technetium‐99m sestamibi imaging for assessment of myocardial viability in patients with coronary artery disease and severe left ventricular dysfunction. J Am Coll Cardiol 1996; 27: 1592–1597 [DOI] [PubMed] [Google Scholar]
  • 24. Levine MG, McGill CC, Ahlberg AW, White MP, Giri S, Shareef B, Waters D, Heller GV: Functional assessment with electrocardiographic gated single‐photon emission computed tomography improves the ability of technetium‐99m sestamibi myocardial perfusion imaging to predict myocardial viability in patients undergoing revascularization. Am J Cardiol 1999; 83: 1–5 [DOI] [PubMed] [Google Scholar]
  • 25. Caner B, Beller GA: Are technetium‐99m‐labeled myocardial perfusion agents adequate for detection of myocardial viability?. Clin Cardiol 1998; 21: 235–242 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Galassi AR, Tamburino C, Grassi R, Foti R, Mammana C, Virgilio A, Licciardello G, Musumeci S, Giuffrida G: Comparison of technetium 99m‐tetrofosmin and thallium‐201 single photon emission computed tomographic imaging for the assessment of viable myocardium in patients with left ventricular dysfunction. J Nucl Cardiol 1998; 5: 56–63 [DOI] [PubMed] [Google Scholar]
  • 27. Nicolai E, Cuocolo A, Acampa W, Varrone A, Pace L, Salvatore M: Exercise‐rest Tc‐99m tetrofosmin SPECT in patients with chronic ischemic left ventricular dysfunction: Direct comparison with TI‐201 reinjection. J Nucl Cardiol 1999; 6: 270–277 [DOI] [PubMed] [Google Scholar]
  • 28. Bax JJ, Cornel JH, Visser FC, Fioretti PM, van Lingen A, Huitink JM, Kamp O, Nijland F, Roelandt JR, Visser CA: Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine‐18 fluorodeoxyglucose single‐photon emission computed tomography. J Am Coll Cardiol 1997; 30: 377–383 [DOI] [PubMed] [Google Scholar]
  • 29. DePuey EG, Ghesani M, Schwartz M, Friedman M, Nichols K, Salensky H: Comparative performance of gated perfusion SPECT wall thickening, delayed thallium uptake, and F‐18 fluorodeoxy‐glucose SPECT in detecting myocardial viability. J Nucl Cardiol 1999; 6: 418–428 [DOI] [PubMed] [Google Scholar]
  • 30. Srinivasan G, Kitsiou AN, Bacharach SL, Bartlett ML, Miller‐Davies C, Dilsizian V: [18F]fluorodeoxyglucose single photon emission computed tomography. Can it replace PET and thallium SPECT for the assessment of myocardial viability? Circulation 1998; 97: 843–850 [DOI] [PubMed] [Google Scholar]
  • 31. Udelson JE: Steps forward in the assessment of myocardial viability in left ventricular dysfunction. Circulation 1998; 97: 833–838 [DOI] [PubMed] [Google Scholar]
  • 32. Morguet AJ, Schelbert HR: Assessment of viability with fluorine‐18 fluorodeoxyglucose positron emission tomography In Nuclear Cardiology: State of the Art and Future Directions, 2nd ed., p. 550 (Eds. Zaret BL, Beller GA.). St. Louis: Mosby, 1999. [Google Scholar]
  • 33. Maddahi J, Schelbert H, Brunker R, Di Carli M: Role of thallium‐201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction. J Nucl Med 1994; 35: 707–715 [PubMed] [Google Scholar]
  • 34. Marwick TH: Stress echocardiography with non‐exercise techniques: Principles, protocols interpretation, and clinical applications In The Practice of Clinical Echocardiography, p. 237 (Ed. Otto CM.). Philadelphia: W. B. Saunders, 1997. [Google Scholar]
  • 35. Dilsizian V: Myocardial viability: Contractile reserve or cell membrane integrity?. J Am Coll Cardiol 1996; 28: 443–446 [DOI] [PubMed] [Google Scholar]
  • 36. Rambaldi R, Poldermans D, Bax JJ, Boersma E, Valkema R, Elhendi A, Vletter WB, Fioretti PM, Roelandt JR, Krenning EP: Dobutamine stress echocardiography and technetium‐99m‐tetrofosmin/fluorine 18‐fluorodeoxyglucose single‐photon emission computed tomography and influence of resting ejection fraction to assess myocardial viability in patients with severe left ventricular dysfunction and healed myocardial infarction. Am J Cardiol 1999; 84: 130–134 [DOI] [PubMed] [Google Scholar]
  • 37. Rahimtoola SH: Importance of diagnosing hibernating myocardium: How and in whom?. J Am Coll Cardiol 1997; 30: 1701–1706 [DOI] [PubMed] [Google Scholar]
  • 38. Iskander S, Iskandrian AE: Prognostic utility of myocardial viability assessment. Am J Cardiol 1999; 83: 696–702 [DOI] [PubMed] [Google Scholar]
  • 39. Eitzman D, Al‐Aouar Z, Kanter HL, vom Dahl J, Kirsh M, Deeb GM, Schwaiger M: Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992; 20: 559–565 [DOI] [PubMed] [Google Scholar]
  • 40. Lee KS, Marwick TH, Cook SA, Go RT, Fix JS, James KB, Sapp SK, MacIntyre WJ, Thomas JD: Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 1994; 90: 2687–2694 [DOI] [PubMed] [Google Scholar]
  • 41. Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, Czernin J, Rokhsar S, Stevenson LW, Laks H, Hawkins R, Schelbert HR, Phelps ME, Maddahi J: Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994; 73: 527–533 [DOI] [PubMed] [Google Scholar]
  • 42. Di Carli MF, Maddahi J, Rokhsar S, Schelbert HR, Bianco‐Batlles D, Brunken RC, Fromm B: Long‐term survival of patients with coronary artery disease and left ventricular dysfunction: Implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg 1998; 116: 997–1004 [DOI] [PubMed] [Google Scholar]
  • 43. Gioia G, Powers J, Heo J, Iskandrian AS: Prognostic value of rest‐redistribution tomographic thallium‐201 imaging in ischemic cardiomyopathy. Am J Cardiol 1995; 75: 759–762 [DOI] [PubMed] [Google Scholar]
  • 44. vom Dahl J, Altehoefer C, Sheehan FH, Buechin P, Schulz G, Schwarz ER, Koch KC, Uebis R, Messmer BJ, Buell U, Hanrath P: Effect of myocardial viability assessed by technetium‐99m‐sestamibi SPECT and fluorine‐18‐FDG PET on clinical outcome in coronary artery disease. J Nucl Med 1997; 38: 742–748 [PubMed] [Google Scholar]
  • 45. Morse RW, Noe S, Carvalho J Jr, Balingit A, Taylor AJ: Rest‐ redistribution 201TI single‐photon emission CT imaging for determination of myocardial viability: Relationship among viability, mode of therapy, and long‐term prognosis. Chest 1999; 115: 1621–1626 [DOI] [PubMed] [Google Scholar]
  • 46. Haas F, Haehnel C, Picker W, Nekolla S, Martinoff S, Meisner H, Schwaiger M: Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997; 30: 1693–1700 [DOI] [PubMed] [Google Scholar]
  • 47. Afridi I, Grayburn PA, Panza JA, Oh JK, Zoghbi WA, Marwick TH: Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction. J Am Coll Cardiol 1998; 32: 921–926 [DOI] [PubMed] [Google Scholar]
  • 48. Meluzin J, Černý J, Frélich M, Štětka F, Špinarová L, Popelová J, Štípal R: Prognostic value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 1998; 32: 912–920 [DOI] [PubMed] [Google Scholar]
  • 49. Senior R, Kaul S, Lahiri A: Myocardial viability on echocardiography predicts long‐term survival after revascularization in patients with ischemic congestive heart failure. J Am Coll Cardiol 1999; 33: 1848–1854 [DOI] [PubMed] [Google Scholar]
  • 50. Bax JJ, Poldermans D, Elhendy A, Cornel JH, Boersma E, Rambaldi R, Roelandt JRTC, Fioretti PM: Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. J Am Coll Cardiol 1999; 34: 163–169 [DOI] [PubMed] [Google Scholar]
  • 51. Pasquet A, Robert A, D'Hondt AM, Dion R, Melin JA, Vanover‐schelde JLJ: Prognostic value of myocardial ischemia and viability in patients with chronic left ventricular ischemic dysfunction. Circulation 1999; 100: 141–148 [DOI] [PubMed] [Google Scholar]
  • 52. Chaundry FA, Tauke JT, Alessandrini R, Vardi G, Parker MA, Bonow RO: Prognostic implications of myocardial contractile reserve in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 1999; 34: 730–738 [DOI] [PubMed] [Google Scholar]
  • 53. Ragosta M, Beller GA, Watson DD, Kaul S, Gimple LW: Quantitative planar rest‐redistribution 201TI imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993; 87: 1630–1641 [DOI] [PubMed] [Google Scholar]
  • 54. Petretta M, Cuocolo A, Nicolai E, Acampa W, Salvatore M, Bonaduce D: Combined assessment of left ventricular function and rest‐redistribution regional myocardial thallium‐201 activity for prognostic evaluation of patients with chronic coronary artery disease and left ventricular dysfunction. J Nucl Cardiol 1998; 5: 378–386 [DOI] [PubMed] [Google Scholar]
  • 55. Beller GA: Introduction In Nuclear Cardiology: State of the Art and Future Directions, 2nd ed., p. 21 (Eds. Zaret BL, Beller GA.). St. Louis: Mosby, 1999. [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES